Research shows that digital videos led to increased knowledge and interventions, but access for vulnerable populations must be improved.
Similar health risks for colorectal cancer were observed in both African Americans and whites, though this study indicated that benefit from greater adherence may be higher at the population level for African Americans.
This research has the potential to aid in the development of new strategies for early detection of relapse in pediatric patients with ALL, and the development of treatments to counter clinical occurrence.
These results highlight the increased prevalence of cardiovascular risk factors in these patients, and the need for personalized risk assessments for cardiac complications following cardiotoxic therapies.
This data could present a non-invasive option for characterizing tumor heterogeneity to improve personalized prognosis and treatment of patients with breast cancer.
Idelalisib May Induce More Favorable Outcomes in Clinical Trial Participants, Versus Medicare Beneficiaries
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia.
This study highlighted the need for novel therapies in myelofibrosis treatment, given that salvage therapies could potentially improve patient outcomes.
Researchers indicated the importance in improving access to and uptake of CRC screening in these underserved populations.
The drug has demonstrated the ability to reduce neutropenia induced by chemotherapy without affecting bone marrow or blood-G-CSF levels.
Although researchers determined which regimen was preferred among physicians in treating metastatic colorectal cancer, they found that shared decision-making should include observation as an acceptable option.
Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors.
In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies.
The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.
Researchers assessed whether ctDNA could accurately differentiate metastases during the neoadjuvant period after surgery to guide therapy adaptation.
Researchers indicated that this sort of non-pharmaceutical programming is warranted to enhance quality of life as the cancer population continues to grow.